Drug
Bimatoprost clinical trials
Also written LUMIGAN® and LATISSE®.
- studies test it
- 77
- open now
- 1
- in phase 3
- 22
- first study started
- 2001
Keep track of what changes. Save the Bimatoprost studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
72 studies that test it; most in 2011 (10)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 3 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 5 |
| 2008 | 2 |
| 2009 | 8 |
| 2010 | 6 |
| 2011 | 10 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 5 |
| 2016 | 5 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 5
- Phase 2
- 14
- Phase 3
- 22
- Phase 4
- 33
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
- Glaucoma
- 20
Who runs them
Industry 52 · Other 25
Allergan (36) · AbbVie (4) · ForSight Vision5, Inc. (4) · Innovative Medical (4) · Duke University (2) · University of Miami (2) · Laboratoires Thea (1) · Ahmed Hassan Nouh MD (1)
Often tested with
Tested in the same studies.
Latanoprost (10) · Timolol (10) · Travoprost (9) · Brimonidine (3) · Dorzolamide (2) · Hypromellose Derivatives (2) · Brimonidine Tartrate, Timolol Maleate Drug Combination (1) · Simenepag isopropyl (1)
Studies
Open first, then newest update. How each study uses Bimatoprost is read from its arms, and is right about nine times in ten.
Testing it · 77
- Treatment of Hypopigmented Scars With BimatoprostRecruitingPhase 2Medstar Health Research InstituteNCT06122090Written as Bimatoprost
- Long-term Safety and Efficacy Extension Trial of Bimatoprost SRCompletedPhase 3AbbVieNCT03891446Written as Bimatoprost SR
- Stop Retinal Ganglion Cell Dysfunction StudyTerminatedPhase 3University of MiamiNCT02390284Written as Bimatoprost
- Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3AbbVieNCT03850782Written as Bimatoprost (SR)
- Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3AbbVieNCT02507687Written as Bimatoprost SR
- Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous PatientsCompletedPhase 3Laboratoires TheaNCT03825380Written as Bimatoprost
- A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3AbbVieNCT04285580Written as Bimatoprost SR
- Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia AreataCompletedPhase 1/2Ahmed Hassan Nouh MDNCT05600673Written as Bimatoprost 0.03% solution
- Effect of Microneedling, Bimatoprost and Excimer in Vitiligo TreatmentCompletedEarly Phase 1Medical University of South CarolinaNCT04738149Written as Bimatoprost
- A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3AllerganNCT02636946Written as Bimatoprost SR
- Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension GlaucomaStatus unknownPhase 4Salus UniversityNCT04981886Written as Bimatoprost Ophthalmic
- Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3AllerganNCT02250651Written as Bimatoprost SR
- Topical Bimatoprost for Chemical BlepharoplastyCompletedEarly Phase 1Tulane UniversityNCT02830776Written as bimatoprost 0.03% ophthalmic solution
- Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the USCompletedPhase 4Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00847483Written as Bimatoprost .03% sterile ophthalmic solution
- Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular HypertensionCompletedPhase 3AllerganNCT02247804Written as Bimatoprost SR
- Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular HypertensionCompletedPhase 1/2AllerganNCT01157364Written as bimatoprost 20 µg generation 2
- Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye PressureCompletedNot applicableNorthwestern UniversityNCT02448043Written as Bimatoprost 0.01%
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash HypotrichosisCompletedPhase 3AllerganNCT01391273Written as bimatoprost solution 0.03%
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash HypotrichosisCompletedPhase 3AllerganNCT01391286Written as bimatoprost solution 0.03%
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle GlaucomaCompletedPhase 4Afyon Kocatepe University HospitalNCT03966560Written as Bimatoprost and Timolol
See all 77 studies that test Bimatoprost →
Given in every arm · 2 — Bimatoprost is usual care beside what is tested
As the comparator · 4 — what is tested is compared with Bimatoprost
- A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular HypertensionWithdrawnPhase 3Sun Pharmaceutical Industries LimitedNCT03927443Written as Lumigan
- Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit DoseCompletedPhase 4Laboratoires TheaNCT02017327Written as Lumigan 0.01%
- An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®CompletedPhase 4Alcon ResearchNCT01664039Written as Bimatoprost 0.01% ophthalmic solution
- Bimatoprost in the Treatment of Eyelash HypotrichosisCompletedPhase 3AllerganNCT01698554Written as bimatoprost solution 0.03 %
Codes
What other systems call Bimatoprost · ClinicalTrials.gg INT006613
- MeSH (NLM) D000069580BimatoprostConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) QXS94885MZBIMATOPROSTConfirmed FDA, NLM, Wikidata
- RxNorm 283810Confirmed FDA, Wikidata
- Wikidata Q2393348bimatoprostConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47414BimatoprostOne source FDA
- DrugBank DB00905One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069580 | Bimatoprost | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | QXS94885MZ | BIMATOPROST | Confirmed FDA, NLM, Wikidata |
| RxNorm | 283810 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2393348 | bimatoprost | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47414 | Bimatoprost | One source FDA |
| DrugBank | DB00905 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.